ceritinib trial summary

All type of patients: 1 trials - Hyams

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	no data
progression or death (progression free survival PFS)	no data
heart failure (grade 3)	no data
permanent discontinuation	no data
treatment-related deaths	no data
serious adverse events	no data
hypertension (grade 3)	no data
arterial/venous thromboembolism (grade 3)	no data
gastrointestinal perforation (grade 3)	no data
bleeding (grade 3)	no data
cardiomyopathy (grade 3)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

ALK positive patients: 2 trials - ASCEND-4 - ASCEND 5

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death (overall survival)	0.73 [0.50 1.07]	p=1.00	0	376	1	ASCEND-4,
progression or death (progression free survival PFS)	0.55 [0.42 0.73]	p=0.04	0	376	1	ASCEND-4,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death (overall survival)	no data
progression or death (progression free survival PFS)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 3 trials - Laurie - Dy - Goss

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Ceritinib ALK inhibitors